373110 — Xcell Therapeutics Balance Sheet
0.000.00%
- KR₩33bn
- KR₩39bn
- KR₩2bn
Annual balance sheet for Xcell Therapeutics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Cash | ||||
| Cash and Equivalents | ||||
| Short Term Investments | ||||
| Cash and Short Term Investments | 14,632 | 5,556 | 1,359 | 8,802 |
| Net Total Accounts Receivable | ||||
| Net Total Receivables | 273 | 648 | 623 | 920 |
| Total Inventory | ||||
| Prepaid Expenses | ||||
| Total Other Current Assets | ||||
| Total Current Assets | 15,425 | 7,216 | 4,421 | 10,512 |
| Gross Property, Plant And Equipment | ||||
| Accumulated Depreciation | ||||
| Net Property, Plant And Equipment | 7,515 | 7,372 | 5,355 | 4,472 |
| Net Intangible Assets | ||||
| Long Term Investments | ||||
| Long Term Notes Receivable | ||||
| Other Long Term Assets | ||||
| Total Assets | 23,702 | 15,509 | 10,468 | 16,890 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Current Portion of Long Term Debt / Capital Leases | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 5,258 | 5,187 | 5,443 | 4,906 |
| Long Term Debt | ||||
| Capital Lease Obligations | ||||
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Funded Status | ||||
| Total Liabilities | 7,477 | 7,026 | 8,085 | 7,769 |
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| ESOP Debt Guarantee | ||||
| Other Equity | ||||
| Total Equity | 16,225 | 8,483 | 2,384 | 9,121 |
| Total Liabilities & Shareholders' Equity | 23,702 | 15,509 | 10,468 | 16,890 |
| Total Common Shares Outstanding |